MicroBio Co., Ltd. is a biopharmaceutical company dedicated to the development and commercialization of new drugs. We have a robust product pipeline of 8 products, 3 of which are currently undergoing clinical trials. Our lead product: MS-20 is in phase III and Phase II trials for enhancing NK (natural killer) cells in cancer patients and for improving the quality of lives of liver cancer patients, respectively. WH-1, has been approved for Phase II clinical trials for the treatment of diabetic foot ulcers and also potentially indicated for other chronic wound healing management conditions. Herbiron is in phase III trials for treating iron deficiency anemia.